Polar Capital Holdings Plc Raises Stock Position in Taysha Gene Therapies, Inc. $TSHA

Polar Capital Holdings Plc increased its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 49.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,931,403 shares of the company’s stock after acquiring an additional 2,637,524 shares during the quarter. Polar Capital Holdings Plc’s holdings in Taysha Gene Therapies were worth $43,623,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. acquired a new stake in Taysha Gene Therapies in the second quarter valued at approximately $11,178,000. Barclays PLC grew its holdings in Taysha Gene Therapies by 1,042.8% in the third quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock worth $16,834,000 after purchasing an additional 4,697,611 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Taysha Gene Therapies during the fourth quarter worth $20,471,000. State Street Corp lifted its holdings in shares of Taysha Gene Therapies by 49.1% during the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock valued at $59,345,000 after purchasing an additional 3,553,619 shares during the last quarter. Finally, MPM Bioimpact LLC purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at $6,823,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

NASDAQ TSHA opened at $5.85 on Wednesday. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -15.39 and a beta of 1.19. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. The stock’s fifty day moving average price is $5.83 and its 200 day moving average price is $5.20. Taysha Gene Therapies, Inc. has a 1 year low of $2.25 and a 1 year high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). As a group, equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.5 earnings per share for the current year.

Insider Activity at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the sale, the insider owned 1,136,410 shares in the company, valued at $5,068,388.60. This represents a 14.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

TSHA has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Needham & Company LLC raised their price target on Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. Chardan Capital restated a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Truist Financial upgraded shares of Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Taysha Gene Therapies currently has an average rating of “Buy” and an average price target of $11.64.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.